RecruitingRecruiting
A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)
NCT07850310 · Merck Sharp & Dohme LLC
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses, Food Effect, and Relative Bioavailability of MK-8644 in Healthy Japanese and Non-Japanese Participants and Multiple Doses of MK-8644 in Patients With Mild to Moderate Plaque Psoriasis
About this study
The purpose of this trial is to learn about a trial medicine called MK-8644. This trial is the first time researchers will give MK-8644 to people.
This trial will help researchers learn about the safety of MK-8644 and if participants tolerate it. Tolerate means participants will receive MK-8644 in the trial unless they need to stop it due to health problems.
Eligibility criteria
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
* Is in good health
* Has a BMI between 18 and 36 kg/m\^2, inclusive
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
* Has a history of clinically significant endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
* Has a history of cancer.
* Has a history of significant multiple and/or severe allergies.
* Has positive test(s) for hepatitis B surface antigen (HBsAg), hepatitis C antibodies, tuberculosis, or HIV.
Study design
Enrollment target: 132 participants
Allocation: randomized
Masking: double
Age groups: adult, older_adult
Timeline
Starts: 2026-10-20
Estimated completion: 2027-12-13
Last updated: 2026-10-27
Interventions
Drug: MK-8644Drug: Placebo for MK-8644
Primary outcomes
- • Number of Participants Who Experience an Adverse Event (AE) (Up to approximately 43 days)
- • Number of Participants Who Discontinue Study Due to an AE (Up to approximately 28 days)
Sponsor
Merck Sharp & Dohme LLC · industry
Contacts & investigators
ContactToll Free Number · contact · Trialsites@merck.com · 1-888-577-8839
InvestigatorMedical Director · study_director, Merck Sharp & Dohme LLC
All locations (1)
Nucleus Network ( Site 0001)Recruiting
Melbourne, Victoria, Australia